Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EBIT: 2010-2025

Historic EBIT for Heron Therapeutics (HRTX) over the last 11 years, with Sep 2025 value amounting to -$4.1 million.

  • Heron Therapeutics' EBIT rose 8.19% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 106.16%. This contributed to the annual value of -$11.5 million for FY2024, which is 89.58% up from last year.
  • Per Heron Therapeutics' latest filing, its EBIT stood at -$4.1 million for Q3 2025, which was down 150.03% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' EBIT ranged from a high of $4.2 million in Q4 2024 and a low of -$62.9 million during Q1 2022.
  • In the last 3 years, Heron Therapeutics' EBIT had a median value of -$4.8 million in 2024 and averaged -$11.3 million.
  • Its EBIT has fluctuated over the past 5 years, first dropped by 20.74% in 2022, then soared by 165.74% in 2025.
  • Heron Therapeutics' EBIT (Quarterly) stood at -$53.5 million in 2021, then skyrocketed by 61.98% to -$20.4 million in 2022, then skyrocketed by 49.79% to -$10.2 million in 2023, then spiked by 140.83% to $4.2 million in 2024, then increased by 8.19% to -$4.1 million in 2025.
  • Its last three reported values are -$4.1 million in Q3 2025, -$1.6 million for Q2 2025, and $3.2 million during Q1 2025.